Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-25T09:19:06.762Z Has data issue: false hasContentIssue false

Chapter 6 - Pharmacology of serotonin antagonists

Published online by Cambridge University Press:  05 March 2016

By
Jacob Nouriel  and
Gildasio De Oliveira
Edited by
Tong Joo Gan  and
Ashraf S. Habib
Foreword by
Henrik Kehlet
Tong Joo Gan
Affiliation:
Duke University Medical Center, Durham
Ashraf S. Habib
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Postoperative Nausea and Vomiting
A Practical Guide
 , pp. 53 - 61
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Scuderi, PE. Pharmacology of serotonin antagonists. In: Gan, TJ, ed. Post-Operative Nausea and Vomiting. Pennsylvania: Lippincott Williams & Wilkins, 2003; 41–66.Google Scholar
Gyermek, L. 5-HT(3) receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol 1995; (35): 637–40.CrossRefGoogle Scholar
Kilpatrick, GJ, Jones, BJ, Tyers, MB. Indentification and distribution of 5-HT3 receptors in rat brain using radioligand bind. Nature 1987; 330: 746–8.CrossRefGoogle Scholar
Garud, KL, Godbole, S, Mankar, S, et al. Efficacy and safety of R(+) ondansetron solution in the treatment of nausea and vomiting in children: results of an open-label, non-comparative, prospective clinical study. Indian Med Gazette 2006; 140: 112–14.Google Scholar
Shinde, J, Mandora, VP, Joshi, PK, et al. Efficacy and safety of R-ondansetron 4 mg versus racemic ondansetron 8 mg: results of a randomized, double blind, multicentric clinical trial. Indian Med Gazette 2005; 139: 444–7.Google Scholar
Pritchard, JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol 1992; 19(4 Suppl 10): 9–15.Google ScholarPubMed
Dixon, CM, Colthup, PV, Serabjit-Singh, CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23(11): 1225–30.Google Scholar
Kaiser, R, Sezer, O, Papies, A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20(12): 2805–11.CrossRefGoogle ScholarPubMed
Candiotti, KA, Birnbach, DJ, Lubarsky, DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102(3): 543–9.CrossRefGoogle ScholarPubMed
Gan, TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102(6): 1884–98.CrossRefGoogle ScholarPubMed
Saynor, DA, Dixon, CM. The metabolism of ondansetron. Eur J Clin Oncol 1989; 25(1): S75–S77.Google Scholar
Amantea, MA, Yarboro, C, Forrest, A, et al. Population pharmacokinetics of intravenous and oral ondansetron in patients with systemic lupus erythematosus (SLE). J Clin Pharmacol 1993; 33: 1004.Google Scholar
Figg, WD, Dukes, GE, Pritchard, F, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996; 36: 206–25.CrossRefGoogle ScholarPubMed
Sphar-Schopfer, IA, Lerman, J, Sikich, N, et al. Pharmacokinetics of intravenous ondansetron in health children undergoing ear, nose, and throat surgery. Clin Pharmacol Ther 1995; 58: 316–21.Google Scholar
Tramer, MR, Reynolds, DJM, Moore, RA, et al. Efficacy, dose–response, and safety of ondansetron in prevention of postoperative nausea and vomiting. Anesthesiology 1997; 87: 1277–89.CrossRefGoogle ScholarPubMed
Tramer, MR, Moore, RA, Reynolds, DJM, et al. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ 1997; 314: 1088–92.CrossRefGoogle ScholarPubMed
Tramer, MR, Phillips, C, Reynolds, DJM, et al. Cost-effectiveness of ondansetron for postoperative nausea and vomiting. Anesthesia 1999; 54: 226–34.CrossRefGoogle ScholarPubMed
Tang, J, Wang, B, White, PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost–benefit as a prophylatic antiemetic in the ambulatory setting. Anesth Analg 1998; 86: 274–82.CrossRefGoogle Scholar
Bryson, JC. Clinical safety of ondansetron. Semin Oncol 1992; 19(6 Suppl 15): 26–32.Google ScholarPubMed
Baber, N, Palmer, JL, Frazer, NM, et al. Clinical pharmacology of ondansetron in postoperative nausea and vomiting. Eur J Anesthesiol Suppl 1992; 6: 11–8.Google ScholarPubMed
Tolan, MM, Fuhrman, TM, Tsueda, K, et al. Perioperative extrapyramidal reactions associated with ondansetron [Letter]. Anesthesiology 1990; 90: 340–1.Google Scholar
Halperin, JR, Murphy, B. Extrapyramidal reaction to ondansetron [Letter]. Cancer 2010; 69(5): 1275.CrossRefGoogle Scholar
Gregory, RE, Ettinger, DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998; 55: 173–89.CrossRefGoogle ScholarPubMed
Balfour, JA, Goa, KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy, or surgery. Drugs 1998; 54: 273–98.Google Scholar
Janicki, PK. Cytochrome P450 2DB metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 2005; 11: RA322–238.Google Scholar
Benedict, CR, Arbogast, R, Martin, L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 2006; 28: 53–9.Google Scholar
Kuryshev, Ya, Brown, AM, Wang, L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs within human cardiac ion channels. J Pharmacol Exp Ther 2000; 295: 614–20.Google ScholarPubMed
Keefe, DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002; 7: 65–72.CrossRefGoogle Scholar
Grote, TH, Pineda, LF, Figlin, RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 1997; 3: 45–51.Google ScholarPubMed
Gan, TJ, Diemunsch, P, Habib, AS et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118: 85–113.CrossRefGoogle ScholarPubMed
Newberry, NR, Watkins, CJ, Sprosen, TS, et al. BRL 46460 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 1993; 32: 729–35.CrossRefGoogle Scholar
Gregory, RE, Ettinger, DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical effect. Drugs 1998; 55: 173–89.CrossRefGoogle Scholar
del Giglio, A, Soares, HP, Caparroz, C, et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000; 89(11): 2301–2308.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Jordan, K, Hinke, A, Grothey, A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007; 15(9): 1023–33.CrossRefGoogle ScholarPubMed
White, PF, Tang, J, Hamza, MA, et al. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery. Anesth Analg 2006; 102: 679–83.CrossRefGoogle ScholarPubMed
Gan, TJ, Candiotti, KA, Klein, SM, et al. Double-blind comparison of granisetron, promethazine, or a combination of both for the prevention of postoperative nausea and vomiting in females undergoing outpatient laparoscopies. Can J Anaesth 2009; 56(11): 829–36.CrossRefGoogle ScholarPubMed
Balki, M, Kasodekar, S, Dhumne, S, et al. Granisetron does not prevent post delivery nausea and vomiting during elective cesarean delivery under spinal anesthesia. Anesth Analg 2007; 104: 679–683.CrossRefGoogle ScholarPubMed
Babaoglu, Mo, Bayar, B, Aynacioglu, AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005; 78: 619–26.CrossRefGoogle Scholar
Bloomer, JC, Baldwin, SJ, Smith, GJ, et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994; 38: 557–66.CrossRefGoogle ScholarPubMed
Roche. Prescribing Information: Kytril (granisetron hydrochloride) injection premixed. Research Triangle Park, NC: Roche, 2006.Google Scholar
Janicki, PK, Schuler, HG, Jarzembowski, Tm, et al. Prevention of post-operative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Aneth Analg 2006; 102:1127–33.CrossRefGoogle Scholar
Cieslak, GD, Watch, MF, Phillips, MB, et al. The dose–response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Anesthesiology 1996; 85(5): 1076–85.CrossRefGoogle ScholarPubMed
Cooper, Sm, Arnold, BDC, Rapeport, WG. Inhibition of 5-HT induced axon-reflex flares by BRL 43694, a novel 5-HT3 receptor antagonist. Br J Clin Pharamcol 1988; 25: 106P–7P.Google Scholar
Macor, JE, Gurley, D, Lanthorn, T, et al. The 5-HT3 antagonist tropisetron (ICS 205–930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 2001; 11: 319–21.CrossRefGoogle ScholarPubMed
Kees, F, Farber, L, Bucher, M, et al. Pharmacokinetics of therapeutic doses of tropisetron in health volunteers. Br J Clin Pharmacol 2001; 52:705–7.CrossRefGoogle Scholar
Fischer, V, Baldeck, JP, Tse, FL. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20:603–7.Google ScholarPubMed
Vickers, AE, Fischer, V, Connors, MS, et al. Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivo. Eur J Drug Metabo Pharmacokinet 1996; 21: 43–50.CrossRefGoogle ScholarPubMed
Kaiser, R, Sezer, O, Papies, A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805–11.CrossRefGoogle ScholarPubMed
Zomers, PJW, Langenber, CJM, de Bruijn, KM. Tropisetron for postoperative nausea and vomiting in patients after gynaecological surgery. Br J Anesth 1993; 71: 667–80.CrossRefGoogle ScholarPubMed
Alon, E, Kocian, R, Nett, OR, et al. Tropisetron for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery. Anesth Analg 1996; 82: 238–41.Google ScholarPubMed
Capouet, V, De Pauw, C, Vernet, B, et al. Single dose i.v. tropisetron in the prevention of postoperative nausea and vomiting after gynaecological surgery. Br J Anesth 1996; 76: 54–60.CrossRefGoogle ScholarPubMed
Stoltz, R, Cyong, JC, Shah, A, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44: 520–31.CrossRefGoogle ScholarPubMed
Stoltz, R, Parisi, S, Shah, A, et al. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004; 25: 329–37.CrossRefGoogle ScholarPubMed
Kovac, AL, Eberhart, L, Kotarski, J, et al. Palonosetron 04-07 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008; 107: 439–44.CrossRefGoogle Scholar
Chun, HR, Jeon, IS, Park, SY, et al. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth 2014; 112: 485–90.CrossRefGoogle ScholarPubMed
Moon, YE, Joo, J, Kim, JE, et al. Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study. Br J Anaesth 2012; 108: 417–22.CrossRefGoogle ScholarPubMed
Hirata, T, Funatsu, T, Keto, Y, et al. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 2007; 15: 5–9.CrossRefGoogle ScholarPubMed
Hahm, TS, Ko, JS, Choi, SJ, et al. Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Anaesthesia 2010; 65: 500–4.CrossRefGoogle ScholarPubMed
Mihara, T, Tojo, K, Uchimoto, K, et al. Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Anesth Analg 2013; 117: 329–39.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×